Xeris Biopharma Shares Rally on Lifted Guidance, 3Q Beat

By Elias Schisgall

Shares of Xeris Biopharma rallied after the company lifted its guidance and reported third-quarter results ahead of Wall Street's expectations.

The stock was up 21% at $12.68 in Thursday trading. Shares have gained 62% this year.

The biopharmaceutical company said it now expects revenue this year of between $395 million and $405 million, up from a range of $385 million to $390 million. Xeris is projecting revenue in 2030 of upwards of $1 billion, lifting its target from around $750 million.

Analysts polled by FactSet currently model revenue of $387.9 million this year, rising to $719.2 million in 2030.

"Our strong third quarter performance puts us on a new growth curve that is accelerating our Company's near-term outlook," Chief Executive Officer John Shannon said. "This new trajectory reflects growth from the full enterprise."

The company reported a profit of $11.3 million, or 6 cents a share. That compares with a profit of around $620,000 last year, or breakeven on a per-share basis.

Revenue rose to $107.2 million, up from $74.4 million a year earlier. Product revenue contributed $106.3 million during the quarter.

Analysts were expecting earnings of 3 cents a share on $101.7 million in revenue.

(END) Dow Jones Newswires

November 05, 2026 12:51 ET (17:51 GMT)